Skip to main content
  • Shilpa Medicare Limited ties up with Dr. Reddys Laboratories Limited for production of Sputnik V vaccine

    Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

    The targeted production of the dual vector Sputnik V for the fIrst 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production.

    admin Mon, 05/17/2021 - 14:56
  • Sun Pharma to Make Eli Lillys Baricitinib Drug in India

    Sun Pharma has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company Lilly for expanding access to Lillys drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.

    admin Tue, 05/11/2021 - 16:36
  • U.S. authorises emergency use of Pfizer COVID-19 vaccine for children

    U.S. Food and Drug Administration, FDA, has expanded the Emergency Use Authorization, EUA, for Pfizer COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.

    admin Tue, 05/11/2021 - 15:35
  • DCGI approves 2-DG medicine for moderate to severe COVID-19 cases

    The Drugs Controller General of India, DCGI, has given permission for the emergency use of 2 deoxyD-glucose, 2-DG medicine as an adjunct therapy in moderate to severe Covid-19 cases.

    An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

    admin Sat, 05/08/2021 - 16:06
  • CoVID-19 Project Recruitment at Institute of Life Sciences

    Institute of Life Sciences Bhubaneswar, an autonomous institute of the Department of Biotechnology, Ministry of Science & Technology, Government of India invites applications from Indian Nationals to join in the following positions coterminous with the project duration.

    Project title : Anti-viral screening platform for viral diseases : with special reference to COVID-19.

    admin Fri, 05/07/2021 - 16:56
  • Job for Pharmacists (18 Posts) at Covid 19 Hospitals

    Ballari Covid 19 Hospitals notification for Staff Nurse, Group D, Medical Officer, Pharmacist.

    Post : Pharmacist

    No of Posts : 18
    Qualification : D.Pharm
    Age Limit : upper age limit is 38 years
    Salary : Rs.22000/-

  • NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

    Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

  • RA/SRF Posts at National Institute of Immunology

    The National Institute of Immunology, New Delhi, is a leading research Institute in India with a long-standing reputation for scientific excellence. The institute is equipped with state-of-the-art infrastructure for pursuing research in immunology and allied sciences. The Institute also imparts vigorous long-term research training leading to a Ph.D degree.

  • Recruitment for Pharmacists (6 posts) due to COVID-19 outbreak

    Walk in Interview (Novel Corona Virus (Covid - 19) It is therefore announced that, in order to meet the status of Novel Corona Virus (Covid 19), management of Anand District Hospitals and Covid Care Centers and treatment of Corona Virus sufferers below.  The said posts have to be filled for three months with fixed honorarium.

    Post : Junior Pharmacist

  • Biological E. Limited Gets CDSCO Nod to Start Phase III Clinical Trial of its COVID-19 Vaccine Candidate

    Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company announced that it has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee (SEC).

Subscribe to COVID-19

Search this website